This Pre-Solicitation opportunity from Department Of Health And Human Services was posted on May 5, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
Takara Bio USA – RetroNectin® GMP Grade Reagents
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The National Institutes of Health, through its Clinical Center in Bethesda, Maryland, intends to award a sole-source, firm-fixed-price contract to Takara Bio USA Inc. for the procurement of 15 vials of RetroNectin® GMP grade reagent, product code T202, which is essential for the manufacturing of cellular therapy products used in over 50 intramural clinical trials conducted by the Center for Cellular Engineering. Takara Bio USA is the exclusive manufacturer of this reagent, and no suitable alternatives exist without extensive revalidation and regulatory approval, which could disrupt critical patient treatments. The acquisition is conducted under FAR 13.106-1(b)(1), which permits sole-source procurement when only one supplier can meet the government’s requirements, and falls under simplified acquisition procedures exempt from full competition. Although this notice is not a formal solicitation and does not invite quotations, interested parties may submit a capability statement by May 14, 2026, at 8:00 AM EST to demonstrate their ability to fulfill the requirement. Submissions must include company details, technical capability, proof of original equipment manufacturer authorization, and relevant past performance. The government will review all submissions but retains full discretion to proceed without competition. The contract will be managed under POTS 26-005759, classified under NAICS code 325413 for in vitro diagnostic substance manufacturing, and the reagents will be delivered for use at the NIH Clinical Center in Bethesda, Maryland. All responses must be emailed to Shasheshe Goolsby of the Hospital and Laboratory Support Division.
General Info
Agency
NAICS
Place of Performance
Bethesda, MD, 20892, USASet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Submission Closed
Organization & Contact Information
Full Description
Title:
Takara Bio USA – RetroNectin® GMP Grade Reagents
Product Service Code (PSC): 6550 – In Vitro Diagnostic Substances, Reagents, Test Kits and Sets
NAICS Code: 325413 – In Vitro Diagnostic Substance Manufacturing
Place of Performance:
National Institutes of Health
Clinical Center
Bethesda, MD 20892
POTS: 26-005759
Description
This notice is issued for informational purposes only and does not constitute a request for quotations. A solicitation will not be issued, and quotations will not be requested.
The National Institutes of Health (NIH), Clinical Center, intends to award a sole source firm-fixed-price contract to Takara Bio USA Inc. for the procurement of RetroNectin® GMP grade reagents.
The requirement consists of 15 vials of RetroNectin® GMP grade reagent (Product Code: T202), which are critical for the manufacturing of cellular therapy products within the Center for Cellular Engineering (CCE).
Background
The Center for Cellular Engineering (CCE) supports over 50 intramural clinical trials and manufactures cellular therapy products used in patient care.
Rationale:
Takara Bio USA Inc. is the sole manufacturer of RetroNectin® GMP grade reagent. Substitution is not permissible without revalidation and regulatory approval, which could delay treatment and pose risks to patient care
Authority
This acquisition is being conducted in accordance with:
FAR 13.106-1(b)(1) – Soliciting from a Single Source
Under this authority, the Contracting Officer may solicit from a single source when it is determined that only one source is reasonably available to meet the Government’s requirements.
Acquisitions conducted under FAR Part 13 – Simplified Acquisition Procedures are exempt from the competition requirements of FAR Part 6.
Responses
This is not a request for quotations. However, interested parties may submit a capability statement demonstrating their ability to meet the Government’s requirement.
Responses must include:
- Company name and address
- Technical capability
- Proof of OEM authorization
- Relevant past performance
The Government will evaluate capability statements received in response to this notice. The determination not to compete this requirement is solely within the discretion of the Government.
Submission Instructions
Responses referencing POTS: 26-005759 must be submitted electronically no later than May 14, 2026, at 8:00 AM EST to:
Shasheshe Goolsby
Team Leader
Hospital and Laboratory Support Division
Office of Acquisitions and Logistics Management
National Institutes of Health
Email: shasheshe.goolsby@nih.gov
More opportunities from Department Of Health And Human Services → National Institutes Of Health Olao
Same awarding agency
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 650+ contractors already using CLEATUS
